Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

48 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Inhibition of PI3K pathway increases immune infiltrate in muscle-invasive bladder cancer.
Borcoman E, De La Rochere P, Richer W, Vacher S, Chemlali W, Krucker C, Sirab N, Radvanyi F, Allory Y, Pignot G, Barry de Longchamps N, Damotte D, Meseure D, Sedlik C, Bieche I, Piaggio E. Borcoman E, et al. Oncoimmunology. 2019 Mar 16;8(5):e1581556. doi: 10.1080/2162402X.2019.1581556. eCollection 2019. Oncoimmunology. 2019. PMID: 31069145 Free PMC article.
Efficacy of molecularly targeted agents given in the randomised trial SHIVA01 according to the ESMO Scale for Clinical Actionability of molecular Targets.
Moreira A, Masliah-Planchon J, Callens C, Vacher S, Lecerf C, Frelaut M, Borcoman E, Torossian N, Ricci F, Hescot S, Sablin MP, Tresca P, Loirat D, Melaabi S, Trabelsi-Grati O, Pierron G, Gentien D, Bernard V, Vincent Salomon A, Servant N, Bieche I, Le Tourneau C, Kamal M. Moreira A, et al. Among authors: borcoman e. Eur J Cancer. 2019 Nov;121:202-209. doi: 10.1016/j.ejca.2019.09.001. Epub 2019 Oct 5. Eur J Cancer. 2019. PMID: 31593830
Immune gene expression in head and neck squamous cell carcinoma patients.
Lecerf C, Kamal M, Vacher S, Chemlali W, Schnitzler A, Morel C, Dubot C, Jeannot E, Meseure D, Klijanienko J, Mariani O, Borcoman E, Calugaru V, Badois N, Chilles A, Lesnik M, Krhili S, Choussy O, Hoffmann C, Piaggio E, Bieche I, Le Tourneau C. Lecerf C, et al. Among authors: borcoman e. Eur J Cancer. 2019 Nov;121:210-223. doi: 10.1016/j.ejca.2019.08.028. Epub 2019 Oct 5. Eur J Cancer. 2019. PMID: 31593831
Fine-needle aspiration as an alternative to core needle biopsy for tumour molecular profiling in precision oncology: prospective comparative study of next-generation sequencing in cancer patients included in the SHIVA02 trial.
Dupain C, Masliah-Planchon J, Gu C, Girard E, Gestraud P, Du Rusquec P, Borcoman E, Bello D, Ricci F, Hescot S, Sablin MP, Tresca P, de Moura A, Loirat D, Frelaut M, Vincent-Salomon A, Lecerf C, Callens C, Antonio S, Franck C, Mariani O, Bièche I, Kamal M, Le Tourneau C, Servois V. Dupain C, et al. Among authors: borcoman e. Mol Oncol. 2021 Jan;15(1):104-115. doi: 10.1002/1878-0261.12776. Epub 2020 Sep 15. Mol Oncol. 2021. PMID: 32750212 Free PMC article.
Prognostic value of intratumoral Fusobacterium nucleatum and association with immune-related gene expression in oral squamous cell carcinoma patients.
Neuzillet C, Marchais M, Vacher S, Hilmi M, Schnitzler A, Meseure D, Leclere R, Lecerf C, Dubot C, Jeannot E, Klijanienko J, Mariani O, Calugaru V, Hoffmann C, Lesnik M, Badois N, Borcoman E, Piaggio E, Kamal M, Le Tourneau C, Bieche I. Neuzillet C, et al. Among authors: borcoman e. Sci Rep. 2021 Apr 12;11(1):7870. doi: 10.1038/s41598-021-86816-9. Sci Rep. 2021. PMID: 33846399 Free PMC article.
Prognostic value of tumor mutational burden in patients with oral cavity squamous cell carcinoma treated with upfront surgery.
Moreira A, Poulet A, Masliah-Planchon J, Lecerf C, Vacher S, Larbi Chérif L, Dupain C, Marret G, Girard E, Syx L, Hoffmann C, Jeannot E, Klijanienko J, Guillou I, Mariani O, Dubray-Vautrin A, Badois N, Lesnik M, Choussy O, Calugaru V, Borcoman E, Baulande S, Legoix P, Albaud B, Servant N, Bieche I, Le Tourneau C, Kamal M. Moreira A, et al. Among authors: borcoman e. ESMO Open. 2021 Aug;6(4):100178. doi: 10.1016/j.esmoop.2021.100178. Epub 2021 Jun 9. ESMO Open. 2021. PMID: 34118772 Free PMC article.
Phase I trial of copanlisib, a selective PI3K inhibitor, in combination with cetuximab in patients with recurrent and/or metastatic head and neck squamous cell carcinoma.
Marret G, Isambert N, Rezai K, Gal J, Saada-Bouzid E, Rolland F, Chausson M, Borcoman E, Alt M, Klijanienko J, Vansteene D, Guigay J, Kamal M, Bièche I, Le Tourneau C; UNICANCER Head, Neck Group. Marret G, et al. Among authors: borcoman e. Invest New Drugs. 2021 Dec;39(6):1641-1648. doi: 10.1007/s10637-021-01152-z. Epub 2021 Jul 28. Invest New Drugs. 2021. PMID: 34322775 Clinical Trial.
Genomic Alterations in Head and Neck Squamous Cell Carcinoma: Level of Evidence According to ESMO Scale for Clinical Actionability of Molecular Targets (ESCAT).
Marret G, Bièche I, Dupain C, Borcoman E, du Rusquec P, Ricci F, Hescot S, Sablin MP, Tresca P, Bello D, Dubot C, Loirat D, Frelaut M, Lecerf C, Le Tourneau C, Kamal M. Marret G, et al. Among authors: borcoman e. JCO Precis Oncol. 2021 Nov;5:215-226. doi: 10.1200/PO.20.00280. JCO Precis Oncol. 2021. PMID: 34994597 Review.
48 results